An Observational Study to Explore Clinical Characteristics of the Patients With T1 Non-small Cell Lung Cancer
NCT ID: NCT03413956
Last Updated: 2018-05-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
10885 participants
OBSERVATIONAL
2017-12-01
2018-03-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Explore Clinical Characteristics and Prognoses of N2 Patients With Non-small Cell Lung Cancer
NCT03429192
A Study to Explore Prognoses of NSCLC Patients Complicated With Oligometastases
NCT03427541
A Study to Evaluate Effectiveness of Sublobar Dissection in Patients With Non-small Cell Lung Cancer
NCT03427567
Comparison of Segmentectomy Versus Lobectomy for Non-small Cell Lung Cancer ≤ 2 cm in the Middle Third of the Lung Field
NCT04944563
Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Associated With Chinese Patients With Advanced Lung Cancer
NCT03505515
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NSCLC patients with lymph metastases
Pathologically diagnosed patients with T1 non-small cell lung cancer complicated with lymph metastases after surgeries
Surgeries
Surgeries
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Surgeries
Surgeries
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Pathologically diagnosed patients with T1 non-small cell lung cancer;
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jiangsu Cancer Institute & Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Feng Jiang
Associate professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lin Xu
Role: PRINCIPAL_INVESTIGATOR
Jiangsu Cancer Institute and Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China
China People's Liberation Army Hospital
Beijing, Beijing Municipality, China
Henan cancer hospital
Zhengzhou, Henan, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Tongji Hospital Affiliated to Tongji Medical College, Huaxi Technology University
Wuhan, Hubei, China
Jiangsu Cancer Institute and Hospital
Nanjing, Jiangsu, China
Xi'an Tangdu Hospital
Xi'an, Shaanxi, China
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China
West China Hospital
Chengdu, Sichuan, China
First Hospital Affiliated to Medical College, Zhejiang University
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JS-LC-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.